Class II — Potential Health Hazard

Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

ZARAH¿ Drospirenone/ Ethinyl Estradiol Tablets Recalled by Watson Laboratories Inc Due to Failed Tablet/Capsule Specification; tablet breakage while pushing through...

Date: February 13, 2013
Company: Watson Laboratories Inc
Status: Terminated
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Watson Laboratories Inc directly.

Affected Products

ZARAH¿ Drospirenone/ Ethinyl Estradiol Tablets, 3.0 mg/0.03 mg, Rx only, 3 tablet dispensers, 28 tablets each, Manuf. by: Watson Laboratories, Inc., Corona, CA 92880. USA; Distributed by: Watson Pharma, Inc., Corona, CA 92880 USA. NDC 52544-981-31 Carton; NDC 52544-981-28

Quantity: 136,720 cartons

Why Was This Recalled?

Failed Tablet/Capsule Specification; tablet breakage while pushing through the blister pack (dispenser) .

Where Was This Sold?

This product was distributed nationwide across all 50 states.

Affected (51 states)Not affected

About Watson Laboratories Inc

Watson Laboratories Inc has 22 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report